FDA Approves Rituxan for Chronic Lymphocytic Leukemia
The US Food and Drug Administration has approved Rituxan (rituximab) to treat certain patients with chronic lymphocytic leukemia.
The US Food and Drug Administration has approved San Francisco-based Genentech’s (a member of the Roche Group) Rituxan (rituximab) to treat certain patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow cancer.
Rituxan, an blockbuster cancer drug, is intended for patients with CLL who are beginning chemotherapy for the first time and for those who have not responded to other cancer drugs for CLL. Rituxan is administered with two other chemotherapy drugs, fludarabine and cyclophosphamide.
This is the third drug approved for the treatment of CLL since 2008. The
FDA approved Arzerra (ofatumumab) in October 2009, for patients whose cancer is no longer being controlled by other forms of chemotherapy, and Treanda (bendamustine) in March 2008, for patients with CLL who had not received prior treatment.
Rituxan is also used in combination with other cancer medicines to treat non-Hodgkin's lymphoma. It is also used in combination with another drug called methotrexate to treat symptoms of adult rheumatoid arthritis.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
